This reports provides a data-driven overview of the current and future competitive landscape in RP therapeutics.
More than 1,000,000 diagnosed prevalent cases of RP are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for RP.
The treatment guidelines for RP have been well established globally. Roche’s Luxturna (voretigene neparvovec) dominate the RP market.
Majority of RP pipeline assets are protein and peptide activator, followed by receptor activator.
A total of 107 clinical trials were initiated for RP in the past 10 years, Phase III trials made up 12.15% of the total trials.
Licensing agreement was the predominant deal type in South America, Africa, Asia-Pacific and North America. In Europe, partnership deals were notably widespread.
Scope
GlobalData’s RP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the RP market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Report Scope
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview - Diagnosed Prevalent Cases of RP in 2024 and 2029
Treatment Overview
Treatment Guidelines
Treatment Algorithm
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in RP
Marketed Drugs - Overview by Mechanism of Action
Marketed Drugs - Overview by Route of Administration
Marketed Drug Profile - Roche's Luxturna
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy
Marketed Drugs - Time to Pricing and Reimbursement for Luxturna
Pipeline Drugs Assessment
Pipeline Drugs Overview - Phase III and Phase II Pipeline Drugs in RP
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in RP
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Ophthalmology and RP
Clinical Trials Assessment
Clinical Trials in RP - Historical Overview
Clinical Trials in RP - Overview by Phase
Clinical Trials in RP - Overview by Status
Clinical Trials in RP - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in RP - Trials with a Virtual Component
Clinical Trials in RP - Geographic Overview
Clinical Trials in RP - Single-Country and Multinational Trials by Region
Clinical Trials in RP - Top Sponsors with Breakdown by Phase
Clinical Trials in RP - Top Sponsors with Breakdown by Status
Clinical Trials in RP - Overview by Endpoint Status
Clinical Trials in RP - Overview by Race and Ethnicity
Clinical Trials in RP - Enrollment Data
Clinical Trials in RP - Overview of Sites by Geography
Clinical Trials in RP - Top 20 Countries for Trial Sites